1/22
04:00 pm
plrx
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/22
08:00 am
plrx
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
Medium
Report
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
1/2
08:00 am
plrx
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
11/21
08:00 am
plrx
Pliant Therapeutics to Participate in Upcoming Investor Events
Low
Report
Pliant Therapeutics to Participate in Upcoming Investor Events
11/18
06:00 pm
plrx
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Medium
Report
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
11/8
12:31 pm
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Medium
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
11/7
04:18 pm
plrx
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/7
04:05 pm
plrx
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Low
Report
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
11/6
08:00 am
plrx
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
Medium
Report
Pliant Therapeutics to Participate in the Stifel Healthcare Conference